首页> 外文期刊>Current proteomics >Identification of Novel Inhibitors for Disrupting EZH2-EED Interactions Involved in Cancer Epigenetics: An In-Silico Approach
【24h】

Identification of Novel Inhibitors for Disrupting EZH2-EED Interactions Involved in Cancer Epigenetics: An In-Silico Approach

机译:用于破坏癌症表观遗传学中的EZH2 eed相互作用的新抑制剂:硅化的方法

获取原文
获取原文并翻译 | 示例
           

摘要

Background: The modulation of the chromatin structure and repression of the transcription process has been done by Polycomb Repressive Complex 2 (PRC2) due to trimethylation of LYS27 of histone H3 (H3K27me3). This process is necessary for protein proteininteraction (PPI) between EZH2 and EED catalytic subunits. The dysregulation of this complex is responsible for tumorigenesis and progression, making it an important cancer epigenetic therapeutic target. However, until now, there is only one FDA-approved drug called Astemizole has been reported to disrupt interactions between EZH2-EED.
机译:背景:由于组蛋白H3(H3K27ME3)的三甲基化,通过Polycomb压抑复合物2(PRC2)进行了染色质结构和转录过程的抑制。 该方法对于EZH2和EED催化亚基之间的蛋白质蛋白质串联(PPI)是必需的。 这种复合体的失调负责肿瘤内酯和进展,使其成为重要的癌症表观遗传治疗靶标。 然而,到目前为止,只有一个称为Asemizole的FDA批准的药物据报道,以破坏EzH2 eed之间的相互作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号